drugset / Trial / NCT04232839
A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body
RandomizedCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to select a formulation principle (tablet vs. capsule) and to optimize the identified extended release formulation of BI 894416, if needed.
Timeline
- Start
- 2020-02-25
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
Outcome
Outcome not reported
Stopped: “Due to company decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 894416 | Unknown | 60 mg | Oral |
| Subject | BI 894416 | Unknown | 62.5 mg | Oral |
Indications
No indication recorded.